A citation-based method for searching scientific literature

E J Herman, M Bubser, P J Conn, C K Jones. Handb Exp Pharmacol 2012
Times Cited: 31







List of co-cited articles
406 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Metabotropic glutamate receptors: physiology, pharmacology, and disease.
Colleen M Niswender, P Jeffrey Conn. Annu Rev Pharmacol Toxicol 2010
22

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
Sandeep T Patil, Lu Zhang, Ferenc Martenyi, Stephen L Lowe, Kimberley A Jackson, Boris V Andreev, Alla S Avedisova, Leonid M Bardenstein, Issak Y Gurovich, Margarita A Morozova,[...]. Nat Med 2007
780
19

The mGluR theory of fragile X mental retardation.
Mark F Bear, Kimberly M Huber, Stephen T Warren. Trends Neurosci 2004
19

Pharmacology and functions of metabotropic glutamate receptors.
P J Conn, J P Pin. Annu Rev Pharmacol Toxicol 1997
19


Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders.
Kenji Hashimoto, Berend Malchow, Peter Falkai, Andrea Schmitt. Eur Arch Psychiatry Clin Neurosci 2013
157
16


Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
J H Krystal, L P Karper, J P Seibyl, G K Freeman, R Delaney, J D Bremner, G R Heninger, M B Bowers, D S Charney. Arch Gen Psychiatry 1994
16

Correction of fragile X syndrome in mice.
Gül Dölen, Emily Osterweil, B S Shankaranarayana Rao, Gordon B Smith, Benjamin D Auerbach, Sumantra Chattarji, Mark F Bear. Neuron 2007
681
16


In vitro characterisation of the novel positive allosteric modulators of the mGlu₅ receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat.
Gary Gilmour, Lisa M Broad, Keith A Wafford, Thomas Britton, Ellen M Colvin, Adam Fivush, Francois Gastambide, Brian Getman, Beverly A Heinz, Andrew P McCarthy,[...]. Neuropharmacology 2013
42
12

Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice.
Aubin Michalon, Michael Sidorov, Theresa M Ballard, Laurence Ozmen, Will Spooren, Joseph G Wettstein, Georg Jaeschke, Mark F Bear, Lothar Lindemann. Neuron 2012
343
12

A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.
Bruce J Kinon, Lu Zhang, Brian A Millen, Olawale O Osuntokun, Judy E Williams, Sara Kollack-Walker, Kimberley Jackson, Ludmila Kryzhanovskaya, Natalia Jarkova. J Clin Psychopharmacol 2011
172
12

Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity.
Richard H P Porter, Georg Jaeschke, Will Spooren, Theresa M Ballard, Bernd Büttelmann, Sabine Kolczewski, Jens-Uwe Peters, Eric Prinssen, Jürgen Wichmann, Eric Vieira,[...]. J Pharmacol Exp Ther 2005
229
12

Metabotropic glutamate receptors in the basal ganglia motor circuit.
P Jeffrey Conn, Giuseppe Battaglia, Michael J Marino, Ferdinando Nicoletti. Nat Rev Neurosci 2005
233
12


Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists.
Thomas Papouin, Laurent Ladépêche, Jérôme Ruel, Silvia Sacchi, Marilyne Labasque, Marwa Hanini, Laurent Groc, Loredano Pollegioni, Jean-Pierre Mothet, Stéphane H R Oliet. Cell 2012
431
12

Pomaglumetad methionil: no significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo.
Virginia L Stauffer, Brian A Millen, Scott Andersen, Bruce J Kinon, Lisa Lagrandeur, J P Lindenmayer, Juan Carlos Gomez. Schizophr Res 2013
74
12


A pilot open label, single dose trial of fenobam in adults with fragile X syndrome.
E Berry-Kravis, D Hessl, S Coffey, C Hervey, A Schneider, J Yuhas, J Hutchison, M Snape, M Tranfaglia, D V Nguyen,[...]. J Med Genet 2009
264
12

De novo mutations in schizophrenia implicate synaptic networks.
Menachem Fromer, Andrew J Pocklington, David H Kavanagh, Hywel J Williams, Sarah Dwyer, Padhraig Gormley, Lyudmila Georgieva, Elliott Rees, Priit Palta, Douglas M Ruderfer,[...]. Nature 2014
998
12

A polygenic burden of rare disruptive mutations in schizophrenia.
Shaun M Purcell, Jennifer L Moran, Menachem Fromer, Douglas Ruderfer, Nadia Solovieff, Panos Roussos, Colm O'Dushlaine, Kimberly Chambert, Sarah E Bergen, Anna Kähler,[...]. Nature 2014
897
12

De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia.
G Kirov, A J Pocklington, P Holmans, D Ivanov, M Ikeda, D Ruderfer, J Moran, K Chambert, D Toncheva, L Georgieva,[...]. Mol Psychiatry 2012
525
12

Serine racemase deletion disrupts memory for order and alters cortical dendritic morphology.
L M DeVito, D T Balu, B R Kanter, C Lykken, A C Basu, J T Coyle, H Eichenbaum. Genes Brain Behav 2011
83
12




A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models.
Gene G Kinney, Julie A O'Brien, Wei Lemaire, Maryann Burno, Denise J Bickel, Michelle K Clements, Tsing-Bau Chen, David D Wisnoski, Craig W Lindsley, Philip R Tiller,[...]. J Pharmacol Exp Ther 2005
244
9

Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity.
Jerri M Rook, Meredith J Noetzel, Wendy A Pouliot, Thomas M Bridges, Paige N Vinson, Hyekyung P Cho, Ya Zhou, Rocco D Gogliotti, Jason T Manka, Karen J Gregory,[...]. Biol Psychiatry 2013
76
9

Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity.
Alice L Rodriguez, Mark D Grier, Carrie K Jones, Elizabeth J Herman, Alexander S Kane, Randy L Smith, Richard Williams, Ya Zhou, Joy E Marlo, Emily L Days,[...]. Mol Pharmacol 2010
141
9


mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning.
Jennifer E Ayala, Yelin Chen, Jessica L Banko, Douglas J Sheffler, Richard Williams, Alexandra N Telk, Noreen L Watson, Zixiu Xiang, Yongqin Zhang, Paulianda J Jones,[...]. Neuropsychopharmacology 2009
167
9

Recent advances in the phencyclidine model of schizophrenia.
D C Javitt, S R Zukin. Am J Psychiatry 1991
9


ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities.
Feng Liu, Steve Grauer, Cody Kelley, Rachel Navarra, Radka Graf, Guoming Zhang, Peter J Atkinson, Michael Popiolek, Caitlin Wantuch, Xavier Khawaja,[...]. J Pharmacol Exp Ther 2008
160
9

Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents.
Gene G Kinney, Maryann Burno, Una C Campbell, Lisa M Hernandez, Dana Rodriguez, Linda J Bristow, P Jeffrey Conn. J Pharmacol Exp Ther 2003
181
9

Selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator.
Francois Gastambide, Marie-Caroline Cotel, Gary Gilmour, Michael J O'Neill, Trevor W Robbins, Mark D Tricklebank. Neuropsychopharmacology 2012
70
9

A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling.
M J Noetzel, K J Gregory, P N Vinson, J T Manka, S R Stauffer, C W Lindsley, C M Niswender, Z Xiang, P J Conn. Mol Pharmacol 2013
64
9

Glutamate receptors as therapeutic targets for Parkinson's disease.
Kari A Johnson, P Jeffrey Conn, Colleen M Niswender. CNS Neurol Disord Drug Targets 2009
150
9

Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice.
C Chiamulera, M P Epping-Jordan, A Zocchi, C Marcon, C Cottiny, S Tacconi, M Corsi, F Orzi, F Conquet. Nat Neurosci 2001
431
9

Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study.
J C Pecknold, D J McClure, L Appeltauer, L Wrzesinski, T Allan. J Clin Psychopharmacol 1982
127
9

2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist.
F Gasparini, K Lingenhöhl, N Stoehr, P J Flor, M Heinrich, I Vranesic, M Biollaz, H Allgeier, R Heckendorn, S Urwyler,[...]. Neuropharmacology 1999
644
9

Mechanism based neurotoxicity of mGlu5 positive allosteric modulators--development challenges for a promising novel antipsychotic target.
Sophie Parmentier-Batteur, Peter H Hutson, Karsten Menzel, Jason M Uslaner, Britta A Mattson, Julie A O'Brien, Brian C Magliaro, Thomas Forest, Craig A Stump, Robert M Tynebor,[...]. Neuropharmacology 2014
66
9

The pathophysiology of fragile X (and what it teaches us about synapses).
Asha L Bhakar, Gül Dölen, Mark F Bear. Annu Rev Neurosci 2012
255
9

Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain.
R Shigemoto, S Nomura, H Ohishi, H Sugihara, S Nakanishi, N Mizuno. Neurosci Lett 1993
446
9



LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress.
Darryle D Schoepp, Rebecca A Wright, Louise R Levine, Brenda Gaydos, William Z Potter. Stress 2003
173
9

Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.
Sébastien Jacquemont, Aurore Curie, Vincent des Portes, Maria Giulia Torrioli, Elizabeth Berry-Kravis, Randi J Hagerman, Feliciano J Ramos, Kim Cornish, Yunsheng He, Charles Paulding,[...]. Sci Transl Med 2011
255
9

Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.
Anantha Shekhar, William Z Potter, Jeffrey Lightfoot, John Lienemann, Sanjay Dubé, Craig Mallinckrodt, Frank P Bymaster, David L McKinzie, Christian C Felder. Am J Psychiatry 2008
305
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.